Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma, and told delegates at ASH yesterday why its talquetamab candidate ...

Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of patients with relapsed or refractory ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure The GENE PREP is the latest fully ...